Devendra K Hiwase Selected Research

Therapeutics

2/2024	Special Issue "Advances in Molecular Pathogenesis and Targeted Therapies for Myeloid Neoplasms".
12/2023	The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry.
11/2023	TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
1/2023	Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study.
12/2022	Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms.
11/2022	A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure.
11/2021	Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.
1/2021	Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
12/2019	The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.
6/2013	Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Devendra K Hiwase Research Topics

Disease

11	Neoplasms (Cancer) 03/2024 - 12/2013
6	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021 - 06/2008
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2023 - 02/2014
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/2023 - 12/2017
1	Rheumatoid Arthritis 03/2024
1	Aplastic Anemia (Anemia, Hypoplastic) 01/2024
1	Rare Diseases (Rare Disease) 12/2023
1	Genetic Predisposition to Disease (Genetic Predisposition) 12/2022
1	Leukemia 12/2022
1	Pneumococcal Infections 01/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	Hematologic Neoplasms (Hematological Malignancy) 12/2019
1	Hemolysis 12/2017
1	Aneuploidy (Aneuploid) 12/2016
1	Genomic Instability 12/2013
1	Premature Aging 12/2013
1	Blast Crisis (Blast Phase) 07/2012
1	Multiple Myeloma 01/2008

Drug/Important Bio-Agent (IBA)

3	Imatinib Mesylate (Gleevec)FDA Link 06/2013 - 06/2008
2	Caspase 2IBA 12/2016 - 12/2013
2	Tyrosine Kinase InhibitorsIBA 02/2014 - 07/2012
2	Dasatinib (BMS 354825)FDA Link 06/2013 - 06/2008
1	alpha-hydroxyglutarateIBA 03/2024
1	avatrombopagIBA 01/2024
1	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2024
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2024
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 12/2023
1	Sorafenib (BAY 43-9006)FDA Link 12/2023
1	olutasidenibIBA 07/2023
1	Azacitidine (5 Azacytidine)FDA Link 02/2023
1	DNA (Deoxyribonucleic Acid)IBA 12/2022
1	Core Binding Factor Alpha 2 SubunitIBA 01/2020
1	IsoantibodiesIBA 12/2017
1	AutoantibodiesIBA 12/2017
1	Cysteine Proteases (Cysteine Protease)IBA 12/2016
1	CytokinesIBA 02/2014
1	Monoclonal AntibodiesIBA 02/2014
1	Interleukin-3 (Interleukin 3)IBA 02/2014
1	AntioxidantsIBA 12/2013
1	Proteins (Proteins, Gene)FDA Link 12/2013
1	Phosphotransferases (Kinase)IBA 06/2011

Therapy/Procedure

11	Therapeutics 02/2024 - 06/2011
3	Hematopoietic Stem Cell Transplantation 01/2020 - 01/2008
2	Drug Therapy (Chemotherapy) 12/2021 - 12/2019
1	Aftercare (After-Treatment) 12/2022
1	Platelet Transfusion (Blood Platelet Transfusions) 10/2020
1	Radiotherapy 12/2019
1	Erythrocyte Transfusion 12/2017
1	Stem Cell Transplantation 01/2008